1. Product and business model
Proposed initial track: a defined American-football helmet-liner integration, developed with an equipment manufacturer rather than sold as an unapproved universal add-on. Initial revenue could be engineering/co-development work followed by component supply or licensing, subject to agreements. The unit model below illustrates component sales only; development fees and royalties are not double-counted.
The value proposition is a testable combination of comfort, relevant impact response, repeatability and manufacturability. None is claimed superior before comparison. Broader body protection and other sports are separate expansion options, not included in the initial market calculation.
2. Market: start with a defensible denominator
The NFHS 2025-26 report records 1,081,241 high-school tackle-football participants across formats. Published 27 August 2026. These are participation entries in that reporting scope, not current buyers or a count of unique athletes across all sports. Youth, college, professional and non-U.S. markets are excluded from this worked example. NFHS source.
Customers and procurement
Equipment manufacturers are potential integration partners. Team equipment staff, athletic directors, sports-medicine staff and procurement influence adoption; athletes influence usability. Validate budget authority, compatibility, replacement timing, warranty, liability and servicing in interviews. Start with adult non-impact usability work; minors require an appropriate separate consent and governance process.
Market segments and expansion gates
| Segment | Proposed approach | Gate before inclusion |
|---|---|---|
| American football equipment partners | One integrated system and comparator matrix | Written integration and certification pathway |
| School / college teams | Buyer interviews and supervised usability | Clinical governance, budget and age-specific requirements |
| Rugby / soccer headgear | Separate opportunity research | Rules, wearability and sport-specific benefit evidence |
| Hockey / combat sports / body padding | Independent product specifications | Different impact modes, coverage and standards |
3. Competitive landscape
| Company / category | Publicly described approach | Implication for GRITARMOR |
|---|---|---|
| D3O | Protective-material integration across applications | A responsive material alone is not a unique business model |
| Mips | Relative movement to address rotational loading | Compare complete-system kinematics, not just compression |
| Riddell Axiom3D | Position-specific helmet/lattice integration | Incumbents compete through fit, systems and distribution |
| Guardian Sports | Helmet covers; listed XT $74.99 and XT 2.0 $89.99 at retrieval | Pricing reference only; different construction and channel |
| Instrumented-mouthguard suppliers | Head-kinematics measurement | Potential measurement partners, not substitutes for protection evidence |
Manufacturer statements describe positioning, not independent comparative efficacy. Prices checked 5 September 2026, exclude implied availability and can change. No affiliations are implied.
4. Unit economics: inputs to challenge
Illustrative assumptions: $150 net realized unit price, $60 landed product cost, and 2% of revenue for warranty/transaction allowances. Contribution is therefore $87 per unit, or 58%, before fixed operating expense, validation, capital expenditure and working capital. Supplier quotes, channel margins, returns, duty, logistics and insurance must replace these placeholders.
5. Five-year base scenario
| USD unless stated | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Units (assumption) | 0 | 500 | 5,000 | 20,000 | 50,000 |
| Revenue (derived) | 0 | 75,000 | 750,000 | 3,000,000 | 7,500,000 |
| Fixed operations | 350,000 | 600,000 | 1,000,000 | 1,600,000 | 2,400,000 |
| Validation programme | 150,000 | 250,000 | 500,000 | 800,000 | 400,000 |
| Operating contribution after fixed costs* | (500,000) | (806,500) | (1,065,000) | (660,000) | 1,550,000 |
*Not GAAP earnings. Excludes depreciation, taxes, financing costs and other unmodeled items. Capital expenditure and working capital are additional. Years are stages from project start, not promises for specified calendar years. No commercial sales are allowed before applicable gates.
Capital discipline
With assumed capex of $100k/$100k/$200k/$250k/$400k and net working capital equal to 20% of annual revenue, the modeled peak cumulative cash deficit is $4.28m. A $250k liquidity buffer raises the illustrative capital requirement to $4.53m, assuming all cash is available when needed. This is not a fundraising target approved by the company, a valuation or a vendor quotation. The downloadable diligence model provided to the owner includes sensitivities and an explicit funding-gap check.
6. Execution and financing gates
Stage 1: customer discovery, product specification, prior-art review and reproducible material screening. Stage 2: integrated prototypes, independent testing and non-impact usability. Stage 3: applicable certification, production quality and a controlled commercial pilot. Stage 4: scale only after repeatable quality and a documented sales pipeline. Stage 5: evaluate adjacent applications and publish clinical evidence where generated.
Manufacturing and IP
Qualify formulation control, traceable batches, encapsulation where applicable, dimensional tolerances, shelf life and cleaning compatibility. Use pilot-line yield and failure data before quoting scale economics. Commission freedom-to-operate analysis around formulations, structures, integration and testing. Do not assume that a patent exists, is valid or grants freedom to operate.
Risks and stop conditions
Principal risks are absent or inconsistent benefit, stiffness/rotation trade-offs, certification or integration barriers, intellectual-property conflicts, customer resistance, low manufacturing yield, liability and insufficient working capital. A failed safety or reproducibility gate stops progression; a larger marketing budget does not resolve it.
7. Diligence material and actual traction
Required evidence includes confirmed legal entity and ownership, verified team biographies, raw and independent test reports, risk documentation, supplier quotations, IP counsel findings, customer interviews and signed commercial commitments where they exist. None is represented as already secured here. Request confidential company information directly; it is not exposed through a public data room.